Performance evaluation of Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test for different diagnostic situations
Microbiology Spectrum · 12.12.2023 · 11 (6)
DOI: 10.1128/spectrum.02078-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 12.12.2023. Verfasst von Madoka Kuramitsu und 28 weiteren Autor:innen. Beteiligte Einrichtung: Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases , Tokyo, Japan. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, HTLV-I Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development (AMED).
Abstract (Originalsprache)
Antibody screening tests for human T-cell leukemia virus type 1 (HTLV-1) are performed based on methods such as chemiluminescent enzyme immunoassay (CLEIA), chemiluminescence immunoassay (CLIA), electrochemiluminescence immunoassay, and particle agglutination (PA). Espline HTLV-I/II, a commercially available, easy-to-use, and rapid immunochromatographic antibody test (IC), was developed for situations where expensive instruments and laboratory equipment are not available. In this report, we compared the performance of IC with the above existing tests using diverse samples derived from asymptomatic HTLV-1 carriers and patients with HTLV-1-associated diseases in collaboration with 11 Japanese institutes. We found that IC detected HTLV-1 infection in all samples from HTLV-1-associated diseases, including adult T-cell leukemia, HTLV-1-associated myelopathy, and HTLV-1 uveitis (200/200). The sensitivity of IC compared with CLIA, CLEIA, and PA was 99.2% (363/366), 100% (241/241), and 100% (47/47), respectively, and the specificity was 99.4% (994/1000), 100% (60/60), and 100% (40/40), respectively. The positive and negative predictive values of IC were 99.7% [95% confidence interval (CI): 99.12–99.92] and 99.5% (95% CI: 98.82–99.75), respectively. However, IC had difficulty in correctly judging samples that were diagnosed as seroreactive in other first screening tests but negative by a confirmatory test; for example, of 612 confirmed negative samples that were CLIA seroreactive, 332 samples were IC positive. These results confirmed that IC has sufficient sensitivity and specificity as a screening test for HTLV-1, although, like the other screening tests, it also requires a confirmatory test to determine HTLV-1 infection correctly. IMPORTANCE The World Health Organization estimated that 5–10 million people are infected with human T-cell leukemia virus type 1 (HTLV-1). This number is likely to be underestimated because reliable endemic data are available for only approximately 1.5 billion people worldwide. The point-of-care test is a powerful tool for the easy and quick detection of infections without the requirement for expensive instruments and laboratory equipment. Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test that was evaluated in this study, might significantly advance our understanding of the global epidemiology of HTLV-1 infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Research Center for Biological Products in the Next Generation, National Institute of Infectious Diseases , Tokyo, Japan.
- Department of Hematology and Rheumatology, Graduate School of Medical and Dental Sciences, Kagoshima University , Kagoshima, Japan.
- Division of Neuroimmunology, Joint Research Center for Human Retrovirus Infection, Kagoshima University , Kagoshima, Japan.
- Department of Hematology, Imamura General Hospital , Kagoshima, Japan.
- Division of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, University of Miyazaki , Miyazaki, Japan.
- Department of Clinical Laboratory, University of Miyazaki Hospital , Miyazaki, Japan.
ORCID-Profile: Madoka Kuramitsu
Förderung
- Japan Agency for Medical Research and Development (AMED)
Zitieren
APA
Kuramitsu, M., Momose, H., Uchida, Y., Ishitsuka, K., Kubota, R., Tokunaga, M., Utsunomiya, A., Umekita, K., Hashikura, Y., Nosaka, K., Koh, K. R., Nakamura, H., Sagara, Y., Sobata, R., Satake, M., Nagata, K., Hasegawa, Y., Sasaki, D., Hasegawa, H., …, & Hamaguchi, I. (2023). Performance evaluation of Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test for different diagnostic situations. Microbiology Spectrum, 11(6). https://doi.org/10.1128/spectrum.02078-23
Vancouver
Kuramitsu M, Momose H, Uchida Y, Ishitsuka K, Kubota R, Tokunaga M, et al. Performance evaluation of Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test for different diagnostic situations. Microbiology Spectrum. 2023;11(6). doi:10.1128/spectrum.02078-23
BibTeX
@article{Kuramitsu2023,
author = {Kuramitsu, Madoka and Momose, Haruka and Uchida, Yuichiro and Ishitsuka, Kenji and Kubota, Ryuji and Tokunaga, Masahito and Utsunomiya, Atae and Umekita, Kunihiko and Hashikura, Yuuki and Nosaka, Kisato and Koh, Ki-Ryang and Nakamura, Hitomi and Sagara, Yasuko and Sobata, Rieko and Satake, Masahiro and Nagata, Koh and Hasegawa, Yuri and Sasaki, Daisuke and Hasegawa, Hiroo and Sato, Tomoo and Yamano, Yoshihisa and Hiraga, Kou and Tezuka, Kenta and Ikebe, Emi and Matsuoka, Sahoko and Okuma, Kazu and Watanabe, Toshiki and Miura, Kiyonori and Hamaguchi, Isao},
title = {Performance evaluation of Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test for different diagnostic situations},
journal = {Microbiology Spectrum},
year = {2023},
volume = {11},
number = {6},
doi = {10.1128/spectrum.02078-23}
}
EUVIMED